The EV-303 trial that led to the FDA approval of perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible bladder cancer patients in now published in NEJM. We discuss the results and ponder potential future changes to treating bladder cancer in the future.

Urinary diversion surgeries: https://jamanetwork.com/journals/jamaoncology/fullarticle/2842595